Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Rating of “Buy” by Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS) has been given an average rating of “Buy” by the six analysts that are covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $25.60.

ATXS has been the topic of a number of research reports. Oppenheimer raised their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, December 10th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. FMR LLC grew its position in Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after acquiring an additional 1,767,714 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares during the period. Nantahala Capital Management LLC bought a new position in shares of Astria Therapeutics in the second quarter worth approximately $6,142,000. Redmile Group LLC purchased a new position in shares of Astria Therapeutics in the third quarter valued at about $3,423,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Astria Therapeutics during the 2nd quarter valued at about $2,561,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Performance

Astria Therapeutics stock opened at $9.52 on Thursday. Astria Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $16.90. The firm’s fifty day moving average price is $10.65 and its 200-day moving average price is $10.72. The stock has a market cap of $537.25 million, a P/E ratio of -4.56 and a beta of 0.67.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.